The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes is a science podcast hosted by Unknown Host, with 162 episodes on record and a Required Pod Score of 80.

Unknown Host hosts The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes, a science show with 162 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Daily Roundup| Mirum's Brelovitug Wins Phase 3 on Two Schedules & Kodiak's Zenkuda: 54% Reach Six-Month Dosing

  Sep 29, 202616 minS1

  Mirum's brelovitug met Phase 3 AZURE-1's virus-plus-ALT endpoint on weekly and every-four-week dosing in chronic hepatitis delta; durable liver outcomes were not shown. Kodiak's Zenkuda and tabirafusp were noninferior to aflibercept 2 mg on vision in wet AMD, and 54% of Zenkuda patients reached a 24-week interval; neither was compared with newer alternatives. 4DMT started Phase 3 testing of 4D-150 in diabetic macular edema, while Roche will return emugrobart rights to Chugai after an obesity trial's interim efficacy stop. Also: Egetis won FDA approval for Emcitate (tiratricol) for peripheral thyrotoxicosis in MCT8 deficiency, Adicet reported early prula-cel lupus data, Merck licensed preclinical SPR2015, and BARDA backed SCYNEXIS's SCY-247. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Full Week in Review | Gilead's Anito-cel, Genentech's Gazyva & Myeloma's New Cure Standard

  Sep 28, 202649 minS1

  This full Week in Review is a comprehensive review of the week's covered stories across oncology, kidney and immune disease, respiratory disease, metabolic disease, neuroscience, rare disease and ophthalmology, plus financings, deals and five events ahead. Gilead's anito-cel gets its full peer-reviewed Phase 1 record before a December FDA target; myeloma groups define cure; and Genentech's Gazyva wins approval to reduce relapse risk in childhood-onset nephrotic syndrome. Also in the review: Lilly's once-weekly Onswik approval, Otsuka and Ionis's Phase 3 ulefnersen result in FUS-ALS, Beacon's pivotal laru-zova win, and regulatory, safety and evidence updates across the covered therapeutic areas, followed by the week ahead. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Daily Roundup | Mirum Wins FOP Approval Despite Primary Endpoint Miss & Carvykti's Five-Year Data

  Sep 26, 202612 minS1

  Mirum's Atebrioz (zilurgisertib) wins FDA approval for FOP despite a primary-endpoint miss; Carvykti (ciltacabtagene autoleucel) shows five-year disease control without maintenance in half of 20 myeloma patients. aTyr plans another efzofitimod trial in sarcoidosis. The roundup covers Pharming's Joenja (leniolisib), ADARx's IPO, Canada's Epkinly (epcoritamab) expansion, Novo–Nanexa's long-acting peptide deal, FDA nominee Heidi Overton's hearing, and Medicaid's GENEROUS pricing plan. September 25 edition, published September 26: relative dates and pending events reflect the original reporting cutoff. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Daily Roundup| Merck–Eisai Win Kidney Cancer Approval & Lilly Joins Weekly Insulin Race

  Sep 25, 202611 min

  Welireg plus Lenvima gains FDA approval in advanced clear-cell kidney cancer, with better disease control but no demonstrated survival advantage. Lilly says FDA approved weekly insulin Onswik, entering a market where Novo’s Awiqli is already available. Merck’s remigromig meets its pivotal vision goal, but safety and dosing questions remain. Plus: Acadia advances after a Phase 2 miss; Kyverna reports autoimmune follow-up; Elevar gains bile-duct cancer approval; Takeda’s Adzynma gets a boxed warning; and Gossamer files despite PROSERA’s miss. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  GRAIL's Galleri Vote Puts Label and Coverage in Focus & Roche Posts Phase 3 Kidney Win

  Sep 24, 202613 minS1

  GRAIL’s Galleri won backing from FDA advisers, but the narrow effectiveness split and a missed late-stage-cancer endpoint keep the label and coverage case in focus. Roche and Ionis report that sefaxersen reduced proteinuria in Phase 3 IgA nephropathy, while longer-term kidney-function data remain blinded and Novartis’s Fabhalta (iptacopan) sets the benchmark. Vertex tests inaxaplin in additional APOL1 kidney disease groups, and Amgen’s dazodalibep succeeds in systemic Sjögren’s disease. Plus: Immunovant halts its cutaneous lupus program, Oruka extends psoriasis follow-up, Boehringer Ingelheim signs an Envisagenics cancer-target pact, and Enveda raises $311 million. Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes

Recent guests on The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.